Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

Executive Summary

• Quantum BioPharma announced the peer‑reviewed publication of a double‑blind, placebo‑controlled crossover trial demonstrating that its dietary supplement “unbuzzd” significantly accelerates alcohol metabolism and reduces intoxication symptoms.
• The study showed a >40 % faster reduction in blood alcohol concentration (BAC) within 30 minutes, statistically significant improvements in alertness, heart‑rate stabilization, reduced perceived impairment, and a 67 % decrease in headache severity at four hours.
• No adverse side effects were reported; the formulation is licensed to Unbuzzd Wellness Inc., with Quantum retaining a 19.86 % equity stake and royalty rights on sales.

Key Details

• Trial Design: Double‑blind, randomized, placebo‑controlled crossover (NCT06505239); healthy males and females, ages 21–43, weight 119–232 lb.
• Alcohol Challenge: Participants consumed alcohol to achieve BAC 0.07 %–0.11 %, then received either unbuzzd or placebo.
• Primary Efficacy Endpoint: Rate of BAC decline – >40 % faster in the first 30 min with unbuzzd vs. placebo (statistically significant).
• Secondary Endpoints:
• Alertness: Significant improvement within 30 min; fewer cognitive errors versus placebo.
• Physiologic Effects: Reduced heart‑rate elevation and mitigated blood‑pressure drop during intoxication.
• Perceived Impairment & Mental Fatigue: Statistically lower scores with unbuzzd.
• Hangover Relief: 67 % reduction in headache severity at 4 h; sustained symptom relief through 8 h.
• Safety: No adverse events reported; product well‑tolerated by all participants.
• Publication Details: World Journal of Pharmaceutical and Medical Research, 2026, Vol. 12, Issue 3, pp. 446‑467 (link: https://zenodo.org/records/18873638).
• Commercial Availability: Licensed to Unbuzzd Wellness Inc.; sold as ready‑to‑mix powder sticks in 3‑pack, 8‑pack, and 18‑pack formats via www.unbuzzd.com and Amazon.
• Quantum BioPharma Ownership & Royalties: Retains 19.86 % of Unbuzzd Wellness Inc. (as of Sep 30 2025); royalty of 7 % on sales until cumulative payments reach US$250 M, thereafter 3 % in perpetuity.
• Strategic Implications: Provides clinically validated evidence supporting a consumer‑focused OTC product that may generate significant royalty revenue and enhance Quantum’s portfolio diversification beyond its core neurodegenerative drug pipeline.

Notable Quotes

“The unbuzzd clinical trial has now been published in a peer‑reviewed international journal, and the trial confirms the exceptional overall efficacy of unbuzzd to help reduce the acute effects of alcohol intoxication and hangover, all without causing adverse side effects,” – Dr. Andrzej Chruscinski, Vice President of Clinical and Scientific Affairs, Quantum BioPharma.

“The science and medical communities for centuries have believed there is no way to significantly speed up alcohol metabolism… This publication validates unbuzzd as a responsible aid to reduce BAC, alleviate signs of alcohol intoxication, and assists with the dreaded hangover,” – Anthony Durkacz, Founder and Executive Co‑Chairman, Quantum BioPharma.